The InRange Study
Prof. Rich Bergenstal, endocrinologist and executive director of international Diabetes Center at Health Partners, Minneapolis, presenting glucose variability with second-generation basal insulin analogs Glargine 300 U/ml and Degludec 100 U/ml evaluated by CGM in people with T1DM based on the InRange randomized controlled trial.
![](/.imaging/webp/sanofi-templates/w1080-16-9/dam/campus-sanofi-ae/Articles/image-(23).jpg/jcr:content/image%20(23).jpg)
Related articles
MAT-BH-2200730/V1/Sep2022